Description: Behavioral Science is a powerful tool to enhance customer experience and improve outcomes across the life insurance value chain. This session will cover the foundations of behavioral concepts in a life insurance context and discuss practical areas that can benefit from behavioral science including customer engagement, disclosure, and retention. The session will leverage recent SOA research and specific experience in communication campaigns and call center best practices to translate theory to quantified results. Attendees will leave with an appreciation for potential challenges and practical steps to measure and demonstrate the value of implementing behavioral science.

Description: The life insurance industry has a long tradition of trying to calculate the economic value with different forms of concepts. Especially with reinsurance, which is often a strategic part of a company's operation, it is important to understand the economics of the transactions given the complexities involved. However, despite the focus on economic value creation, the financial metrics demanded by various stakeholders often tie to one or more accounting basis.

Description: Discover investing trends across the life and health industry as insurers seek to navigate rapidly changing rate and market environments. BlackRock will present results from its Peer Risk Study, which models industry holdings based on statutory filings at the CUSIP level. Through the Aladdin risk modeling software, expect a production of deep insights into insurer portfolio risk and return characteristics, as well as exploring how they have evolved. Keep an eye out for a partner to present on the evolution from their perspective. Start learning about what is happening on the asset side of the balance sheet across the industry.

Description: As companies have reported their latest financials for 2023, LDTI is in its full swing for the public companies. Under US GAAP reinsurance accounting methods can be daunting. Add onto this legacy practices related to reinsurance reporting and this may lead to significant unwinding and implementation efforts. This session will discuss industry practices commonly applied to US GAAP reinsurance reported balances such that LDTI adopters can gather deeper insights into the LDTI impact. Specifically, the session will explain the two most popular methods to value reinsurance under LDTI, methods applying a direct measurement of the reinsurance net cost and a method that recognizes ceded asset balances and a cost of reinsurance (“CoRe”). The session will present simplified direct and ceded models to demonstrate how the actuarial balances under LDTI impact GAAP book profits for different underlying products and reinsurance types.

Description: "Population Aging, Global Climate Change and Social Security – Sally Shen, Research Associate, Global Risk Institute, John A. Turner, Ph.D., Director, Pension PolicyClimate Change and Mortality Time for Actuaries to Pay Attention – Sam Gutterman. FSA, CERA, FCAS, FCA, HONFIA, MAAA"

Description: Discover an introduction to decomposing differences in life expectancy by age and cause of death. Take a look into demographic techniques that decompose life expectancies at birth and older ages into the portions contributed by later age groups and causes of death-. These have been in existence for some time and provide a convenient device for analyzing mortality change over time as well as differences between sexes, countries, and ethnic groups. The methods will be described and illustrated by spreadsheet examples.

Description: In this panel discussion, actuarial leaders in the stop-loss marketplace provide their perspectives on recent stop-loss trends. Learn about the most current issues facing self-funded plans and their stop-loss coverage. Take part in a deeper discussion on this topic and more at Oysters, Beers & Large Claim Solutions on Tuesday, June 27, from 4:30-5:30 p.m. PT. This happy hour, featuring drinks and tasty Pacific Northwest oysters will include a discussion on the large claims impacts on the health care market.

Description: This session will provide an analysis of the latest activities and trends in asset-intensive reinsurance (AIR), including life, annuity, long-term care (LTC), and pension risk transfer (PRT) transactions, and their anticipated impact on the industry in the coming years. Speakers will delve into the strategic considerations of reinsurers, the concerns and preferences of insurers, and the perspectives of rating agencies. Through a case study, the session will demonstrate how asset-intensive reinsurance can serve as a capital lever and profitability enhancer within the evolving regulatory landscape. The discussion will highlight how these strategies support insurers' strategic initiatives, enhance internal rates of return (IRR) and other key performance indicators (KPI), facilitate sales growth and product launches, and improve the financial strength of the company. Additionally, as many of these transactions utilize alternative asset classes to enhance yields, the speakers will examine the differences among these asset classes and the key considerations when incorporating or modeling them in actuarial work.

Description: Cayman is a rapidly growing reinsurance domicile with several notable transactions executed in the past few years. We expect this trend to persist as (re)insurers will continue to explore more effective ways to manage their business. In this session, you will gain: - An overview of how the Cayman (re)insurance market has developed over recent years - An introduction to the Cayman regulatory framework - Key considerations for reinsurance structuring and pricing. Join a discussion at the close of the session on the outlook for the Cayman market. You will leave this session with an understanding of the Cayman (re)insurance market, the regulatory framework and key factors that impact reinsurance structuring and pricing.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.